Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Hamilton Rogers who wrote (257)	5/18/2000 4:17:00 PM
From: Skywatcher	Read Replies (1) \| Respond to of 328

NEW YORK (CBS.MW) --Abbott Laboratories and SangStat said they received approval from the FDA to market Gengraf, a lower priced version of cyclosporine, which is used to prevent organ transplant rejection. Gengraf will compete with Neoral, the leading version of cyclosporine, which is marketed by Novartis.Gengraf is interchangeable with Neoral, Abbott (ABT: news, msgs) and SangStat (SANG: news, msgs) said. Cyclosporine is the leading immunosuppressive drug used to prevent graft rejection in transplants.Sales of cyclosporine in the U.S. are about $480 million annually. Shares of Abbott rose 1 15/16 to 38 15/16 while shares of SangStat fell 1 13/16 to 29 15/16. In a press release issued by the companies Monday, Lisa Kory, executive director of Transplant Recipients International Organization Inc. said the new drug will benefit patients since they have to pay for such medicine for the rest of their lives. "Lower-cost, therapeutically equivalent medications are important options for transplant recipients," Kory said in the statement. Gengraf has been given a so-called AB rating by the FDA. An AB rating means a product is therapeutically equivalent to or interchangeable with a reference drug. Under state pharmacy and Medicaid laws, an AB rating allows and, in some cases, mandates substitution of the lower-cost generic drug, Abbott and SangStat said. Things are looking very good for ABT at the moment...charging ahead with the other big drug boys today. Holding 02 40 leaps and feeling good about them...in the money today and 20 months to go. chris

To: Hamilton Rogers who wrote (257)	5/23/2000 1:14:00 PM
From: Skywatcher	Read Replies (1) \| Respond to of 328

From an article last week: Another up-and-comer worth a look is SangStat Medical (SANG), which, along with Abbott Laboratories (ABT), recently won approval from the FDA to market Gengraf, a lower priced version of cyclosporine, which is used to prevent organ transplant rejection. Gengraf will compete with Neoral, the leading version of cyclosporine, which is marketed by Novartis. The two are interchangeable, according to SangStat and Abbott. Cyclosporine is the leading drug used to prevent graft rejection in transplants. Sales of cyclosporine in the United States run about $480 million annually. In May 15 trading, shares of SangStat -- a money-loser, like Geron -- fell $1.91 to $29.94, down from $48 earlier this year. I suggest you take your time choosing the right biotech exposure for your investment needs. The bears might not be done with these biotech prices. Chris

To: Hamilton Rogers who wrote (257)	5/24/2000 4:16:00 PM
From: Skywatcher	Respond to of 328

TAP launches research with IPF PharmaCeuticals LAKE FOREST, Ill., May 24 (Reuters) - TAP Pharmaceutical Products Inc., a joint venture between Abbott Laboratories (NYSE:ABT - news) and Takeda Chemical Industries Ltd. of Japan, on Wednesday said it launched a long-term research collaboration with Germany's IPF PharmaCeuticals GmbH. TAP said it will provide research funding to IPF for a minimum of five years in return for a right of first refusal to exclusive worldwide development and sales rights to IPF discoveries. IPF, which focuses on research on natural human peptides, will receive an undisclosed sum of money for discoveries and royalties on commercial sales. Lots of potential stuff coming out and after that chart showed a beautiful cup and saucer, the strength continues. chris